Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection.

[1]  Katyna Borroto-Esoda,et al.  No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus , 2011, Hepatology.

[2]  C. Chu,et al.  Hepatitis B virus infection , 2009, The Lancet.

[3]  C. Yurdaydın.  Entecavir: a step forward in combating hepatitis B disease , 2008 .

[4]  C. Yurdaydın,et al.  A Novel Mutation Pattern Emerging during Lamivudine Treatment Shows Cross-Resistance to Adefovir Dipivoxil Treatment , 2007, Antiviral therapy.

[5]  Huiling Yang,et al.  In Vitro Susceptibility of Adefovir-Associated Hepatitis B Virus Polymerase Mutations to other Antiviral Agents , 2006, Antiviral therapy.

[6]  C. Mazzucco,et al.  Entecavir resistance is rare in nucleoside naïve patients with hepatitis B , 2006, Hepatology.

[7]  F. Zoulim,et al.  A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV–hepatitis B virus-co-infected patient , 2006, AIDS.

[8]  S. Locarnini,et al.  Antiviral drug resistance: clinical consequences and molecular aspects. , 2006, Seminars in liver disease.

[9]  M. Helm,et al.  Variant of hepatitis B virus with primary resistance to adefovir. , 2006, The New England journal of medicine.

[10]  R. Idilman,et al.  Lamivudine Treatment in Hbeag-Negative Chronic Hepatitis B Patients with Low Level Viraemia , 2005, Antiviral therapy.

[11]  P. Angus,et al.  Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.

[12]  Huiling Yang,et al.  In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. , 2004, Antiviral research.

[13]  R. Rubin,et al.  Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. , 2004, Gastroenterology.

[14]  Michael D. Miller,et al.  The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro , 2003, Journal of Virology.

[15]  Angeline Bartholomeusz,et al.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.

[16]  C. Yurdaydın,et al.  YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine , 2003, Journal of viral hepatitis.

[17]  S. Pahwa,et al.  Patterns of CD8 T cell clonal dominance in response to change in antiretroviral therapy in HIV-infected children , 2000, AIDS.

[18]  L. Stuyver,et al.  Line Probe Assay for Monitoring Drug Resistance in Hepatitis B Virus-Infected Patients during Antiviral Therapy , 2000, Journal of Clinical Microbiology.

[19]  O. Yokosuka,et al.  Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients , 2000, Journal of medical virology.

[20]  M. Buti,et al.  Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. , 1999, Journal of virological methods.

[21]  K. Walters,et al.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine , 1998 .

[22]  J. Wands,et al.  Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective , 1998, Hepatology.

[23]  S. Günther,et al.  A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients , 1995, Journal of virology.